Krystal Biotech (KRYS, Biotechnology) Stock Valuation & Fair Value Significantly overvalued
Krystal Biotech (KRYS, Biotechnology) trades at a blended P/E of 36.9 — about 73% below its historical normal valuation — with a forward growth estimate of 16.8% and a PEG of 2.20. Analysts' one-year estimates have been hit 38% of the time.
Valuation flags
- No notable valuation flags.
Verdict history
tickerseer's rating has been significantly overvalued since 2026-06-14.
Frequently asked questions
Is Krystal Biotech stock overvalued?
At a blended P/E of 36.9 versus its historical normal P/E of 135.5, Krystal Biotech trades about 73% below its typical valuation, with a PEG of 2.20 on 16.8% forward growth — tickerseer currently rates it significantly overvalued.
What is Krystal Biotech's fair value and PEG?
Krystal Biotech trades at a blended P/E of 36.9 against a historical normal P/E of 135.5, a PEG of 2.20, and a forward growth estimate of 16.8%.
Has tickerseer's rating of Krystal Biotech changed?
tickerseer's rating has been significantly overvalued since 2026-06-14.
Industry: Biotechnology. Create a free account to unlock the full analysis — the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.